Tesaro, AnaptysBio collaborate on immune checkpoint inhibitors

Cancer drug developer Tesaro entered the hot immuno-oncology space with an exclusive, worldwide license and collaboration agreement for antibodies from AnaptysBio that target three different immune checkpoint receptors.